Interestingly, these mutations are paralogous to resistance mutations that have been identified after progression on ALK tyrosine kinase inhibitor therapy in ALK fusion-positive lung cancers, and ROS1 tyrosine kinase inhibitor therapy in ROS1 fusion-positive lung cancers [22, 23]. Here, ALK is linked to lung carcinoma.